BioCentury | May 24, 2019
Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
BioCentury | Nov 3, 2014
Finance

Shooting F-stars

F-star Alpha Ltd. 's deal with Bristol-Myers Squibb Co. (NYSE:BMY) last week is the first validation of the parent platform company's strategy of speeding returns by packaging assets into corporations for buyer convenience and seller...
BioCentury | Aug 4, 2014
Finance

Voucher leapfrog

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are hoping to use a newly acquired Priority Review voucher to jump ahead of Amgen Inc. (NASDAQ:AMGN) in the race to be first to market with a...
BC Innovations | Jun 5, 2014
Strategy

Sanford-Burnham goes fourth

Sanford-Burnham Medical Research Institute 's outreach to industry has resulted historically in deals focused either on a narrow range of projects or the work of individual investigators, but the institute also has been seeking broader...
BioCentury | May 19, 2014
Finance

Play it again, Celldex

Investors flocked to Celldex Therapeutics Inc. (NASDAQ:CLDX) after the company announced a cancer immunotherapy partnership with Bristol-Myers Squibb Co. (NYSE:BMY). Buysiders may be hoping the narrow nature of the BMS deal means the biotech isn't...
BioCentury | Dec 16, 2013
Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
BC Week In Review | Sep 23, 2013
Company News

Arbor Pharmaceuticals, Takeda sales and marketing update

Takeda granted Arbor's Arbor Pharmaceuticals Ireland Ltd. subsidiary exclusive rights to commercialize hypertension drugs Edarbi azilsartan medoxomil and Edarbyclor azilsartan medoxomil/chlorthalidone in the U.S. Takeda, which has already launched the products in the U.S., will...
BC Week In Review | Jul 15, 2013
Clinical News

Azor/Sevikar olmesartan/amlodipine regulatory update

FDA issued a drug safety communication warning that hypertension drug olmesartan can cause intestinal problems known as sprue-like enteropathy, which includes symptoms such as severe, chronic diarrhea with substantial weight loss. FDA said it approved...
BC Week In Review | Apr 15, 2013
Company News

Daiichi Sankyo, Kowa sales and marketing update

Daiichi and Kowa said the companies terminated their Japanese commercialization partnership for Kowa's cholesterol drug Livalo pitavastatin and Daiichi's hypertension drug Olmetec olmesartan following a review of sales strategy. Effective July 1, the pharmas will...
BC Week In Review | Oct 8, 2012
Clinical News

Azilsartan medoxomil regulatory update

Takeda said that within the first 8 months of this year, it submitted a regulatory application for azilsartan medoxomil in Hong Kong to treat hypertension. The oral angiotensin II type 1 (AT1) receptor blocker (ARB)...
Items per page:
1 - 10 of 114